Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $0.6 to $6.
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $0.6 to $6.